RT journal article
T1 The role of glucagon after bariatric/metabolic surgery: much more than an “anti-insulin” hormone
A1 Pérez Arana, Gonzalo Martín
A1 Díaz Gómez, Alfredo Luis
A1 Bancalero-de los Reyes, José
A1 Gracia Romero, Manuel Ángel
A1 Ribelles García, Antonio
A1 Visiedo García, Francisco Manuel
A1 González Domínguez, Álvaro
A1 Almorza Gomar, David
A1 Prada Oliveira, José Arturo
A2 Anatomía y Embriología Humana
A2 Estadística e Investigación Operativa
K1 alpha cell
K1 diabetes
K1 glucagon
K1 glucose
K1 incretin
K1 Roux-en-Y gastric bypass
K1 sleeve gastrectomy
AB The biological activity of glucagon has recently been proposed to both stimulate hepatic glucose production and also include a paradoxical insulinotropic effect, which could suggest a new role of glucagon in the pathophysiology type 2 diabetes mellitus (T2DM). An insulinotropic role of glucagon has been observed after bariatric/metabolic surgery that is mediated through the GLP-1 receptor on pancreatic beta cells. This effect appears to be modulated by other members of the proglucagon family, playing a key role in the beneficial effects and complications of bariatric/metabolic surgery. Glucagon serves a dual role after sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). In addition to maintaining blood glucose levels, glucagon exhibits an insulinotropic effect, suggesting that glucagon has a more complex function than simply an “anti-insulin hormone”.
PB Frontiers Media SA
SN 1664-2392
YR 2023
FD 2023
LK http://hdl.handle.net/10498/31488
UL http://hdl.handle.net/10498/31488
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 11-nov-2026